Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.42 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.42 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.42 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.42 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.42 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.42 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.42 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.42 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.42 |
| ▸ | GABRG3 known ✓ | Q99928 | 1/20 | 0.42 |
| ▸ | GABRQ known ✓ | Q9UN88 | 1/20 | 0.42 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL46774 | 0.97 | ALDH1A1 (0.55) | ALDH1A1LMNAHTTKDM4EUSP2 | |
| SCHEMBL26612129 | 0.95 | ALDH1A1 (0.53) | ALDH1A1LMNAHTTKDM4EUSP2 | |
| Water SCHEMBL5420438 | 0.95 | ALDH1A1 (0.53) | ALDH1A1LMNAHTTKDM4EUSP2 | |
| Iodide SCHEMBL30988366 | 0.95 | ALDH1A1 (0.53) | ALDH1A1LMNAHTTKDM4EUSP2 | |
| SCHEMBL3092846 | 0.95 | ALDH1A1 (0.53) | ALDH1A1LMNAHTTKDM4EUSP2 | |
| Hydrochloric Acid SCHEMBL8126712 | 0.89 | ALDH1A1 (0.50) | ALDH1A1LMNAHTTKDM4EUSP2 | |
| Formamide SCHEMBL4699697 | 0.89 | ALDH1A1 (0.50) | ALDH1A1LMNAHTTKDM4EUSP2 | |
| Sulfuric Acid SCHEMBL28174949 | 0.89 | ALDH1A1 (0.49) | ALDH1A1LMNAKDM4EUSP2HPGD | |
| SCHEMBL12633292 | 0.89 | ALDH1A1 (0.62) | ALDH1A1LMNAHTTKDM4EUSP2 | |
| Tert-Butylamine SCHEMBL27942385 | 0.87 | LMNA (0.50) | ALDH1A1LMNAKDM4EUSP2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114144408-B | Large scale preparation of 2,4, 6-trifluoro-N- [6- (1-methyl-piperidine-4-carbonyl) -pyridin-2-yl ] -benzamide hemisuccinate and process and intermediates for preparing 2,4, 6-trifluoro-N- [6- (1-methyl-piperidine-4-carbonyl) -pyridin-2-yl ] -benzamide acetate | 伊莱利利公司 | 2025-04-15 | — | — | CN | claimed |
| EP-3996713-B1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE | LILLY CO ELI (US) | 2024-12-04 | — | — | EP | claimed |
| EP-4410784-A2 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE | Eli Lilly and Company (US) | 2024-08-07 | — | — | EP | claimed |
| US-20240059666-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | ELI LILLY AND COMPANY | 2024-02-22 | — | — | US | claimed |
| US-11827618-B2 | Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate | ELI LILLY AND COMPANY | 2023-11-28 | — | — | US | claimed |
| US-20230250076-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | ELI LILLY AND COMPANY | 2023-08-10 | — | — | US | claimed |
| US-20230250075-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | ELI LILLY AND COMPANY | 2023-08-10 | — | — | US | claimed |
| US-20230137090-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | ELI LILLY AND COMPANY | 2023-05-04 | — | — | US | claimed |
| EP-3996713-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | ELI LILLY AND COMPANY (US) | 2022-05-18 | — | — | EP | claimed |
| CN-114144408-A | Process and intermediates for large scale preparation of 2,4, 6-trifluoro-N- [6- (1-methyl-piperidine-4-carbonyl) -pyridin-2-yl ] -benzamide hemisuccinate and preparation of 2,4, 6-trifluoro-N- [6- (1-methyl-piperidine-4-carbonyl) -pyridin-2-yl ] -benzamide acetate | 伊莱利利公司 | 2022-03-04 | — | — | CN | claimed |
| WO-2021007155-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | ELI LILLY AND COMPANY (US) | 2021-01-14 | — | — | WO | claimed |
| CN-107188921-A | The preparation method of abiraterone derivative and its new solid-state form and purposes | 四川海思科制药有限公司 | 2017-09-22 | — | — | CN | claimed |
| EP-4727599-A2 | POLY(OXAZOLINE) CONJUGATES WITH PENDANT CATIONIC GROUPS AND LIPID NANOPARTICLES AND POLYPLEXES INCLUDING SAME | Serina Therapeutics (AL), Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260078085-A1 | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2026-03-19 | — | — | US | disclosed |
| US-20260021046-A1 | LIPID NANOPARTICLE AND PHARMACEUTICAL COMPOSITION | UNIV HOKKAIDO NAT UNIV CORP (JP) | 2026-01-22 | — | — | US | disclosed |
| US-12503432-B2 | Ionizable lipids for nucleic acid delivery | GLOBAL LIFE SCIENCES SOLUTIONS CANADA ULC (CA) | 2025-12-23 | — | — | US | disclosed |
| EP-0213450-A2 | Aminoacyl derivatives of 4,9-dihydro-10H-pyrido[3,2-b]-thieno-[3,2-e][1,4]diazepinone and of 4,9-dihydro-10H-pyrido[3,2-b]-thieno[3,4-e][1,4]diazepinone, their preparation and pharmaceutical compositions containing them | DOMPE' FARMACEUTICI S.p.A. (IT) | 1987-03-11 | — | — | EP | disclosed |
| US-4556653-A | ANTISECRETORY, ANTIULCER AND ANTISPASMODIC AGENTS | DOMPE' FARMACEUTICA S.P.A. (IT) | 1985-12-03 | — | — | US | disclosed |
| EP-0125607-A2 | Pyrido(1,5)benzodiazepinone derivatives and pharmacological activities thereof | DOMPE' FARMACEUTICI S.p.A. (IT) | 1984-11-21 | — | — | EP | disclosed |
| EP-0000167-A1 | 1,2,3,6-Tetrahydroisonicotinic acid and derivatives thereof, methods and starting products for their preparation, and pharmaceutical compositions containing them. | Krogsgaard-Larsen, Povl (DK) | 1979-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021046-A1 | LIPID NANOPARTICLE AND PHARMACEUTICAL COMPOSITION | FABP1, RHOA, STAT6 | GABRP 3504/4885GABRD 4515/4885GABRA1 3251/4885 |
| US-20240059666-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | LPXN, KDM2A, PMP22 | GABRP 576/4885GABRD 1022/4885GABRA1 345/4885 |
| US-20230250075-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | LPXN, KDM2A, PMP22 | GABRP 576/4885GABRD 1022/4885GABRA1 345/4885 |
| US-11827618-B2 | Processes and intermediate for the large-scale preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide hemisuccinate, and preparation of 2,4,6-trifluoro-n-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide acetate | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, KDM4D, KDM5B | GABRP 365/4885GABRD 1107/4885GABRA1 343/4885 |
| US-20260078085-A1 | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY | NSUN2, NSUN3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | GABRP 3990/4885GABRD 4191/4885GABRA1 4309/4885 |
| US-20230137090-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | LPXN, KDM2A, HTR2A | GABRP 691/4885GABRD 1248/4885GABRA1 432/4885 |
| US-12503432-B2 | Ionizable lipids for nucleic acid delivery | RNASEH1, NSUN3, SLC67A1 | GABRP 3974/4885GABRD 4787/4885GABRA1 4548/4885 |
| US-20230250076-A1 | PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE | LPXN, KDM2A, PMP22 | GABRP 576/4885GABRD 1022/4885GABRA1 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.